| abstract |
The present invention is directed to the compound of formula (II), or a solvate thereof. The invention is also directed to the pharmaceutical use of the compound as an IκB kinase inhibitor, crystalline anhydrous and hydrated forms of the compound, pharmaceutical compositions comprising the compounds of the invention, and stable pharmaceutical products comprising the compound. As an inhibitor of IκB kinase, the compound of the invention, functions via the selective inhibition of IKK, particularly an IKK-2 inhibitor; as well as exhibiting localized activity, as opposed to a systemic activity. Such an inhibitor is particularly useful for treating a patient suffering from or subject to IKK-2 mediated pathological diseases or conditions, e.g., asthma, rhinitis, chronic obstructive pulmonary disorder (COPD), or COPD exacerbations, that could be ameliorated by the targeted administering of the inhibitor. |